Trial Profile

A phase II/III study of BHV-0223 for the treatment of spinocerebellar ataxia.

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 12 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Riluzole (Primary)
Indications Spinocerebellar ataxias
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Nov 2016 According to Biohaven Pharmaceutical media release, company plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
11 Mar 2016 New trial record
03 Mar 2016 According to a Biohaven media release, the company expects to initiate this trial of BHV-0223 for the treatment of spinocerebellar ataxia before the end of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com